文献速递神经肿瘤

拉帕替尼对2型神经纤维瘤病成人脑膜瘤生长的影响

Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
PubMed 文献 · J Neurooncol · 2018-06-08

该回顾性研究纳入8例2型神经纤维瘤病(NF2)患者共17个可评估脑膜瘤,患者接受拉帕替尼1500 mg每日治疗。治疗期间肿瘤总体积61.17 cc较基线61.35 cc变化不大,停药后增至108.86 cc(+77.44%,p=0.0033)。数据提示拉帕替尼可能对NF2患者脑膜瘤有生长抑制作用,支持开展前瞻性研究。

要点

  • 治疗期间脑膜瘤总体积61.17 cc vs 基线61.35 cc,停药后108.86 cc(+77.44%,p=0.0033)。
  • 治疗期间年化生长率均值10.67%、中位数1.32%;停药期间均值20.05%、中位数10.42%。
  • 治疗期间2个肿瘤体积增加>20%,停药期间8个肿瘤体积增加>20%。

核心结论

  • 数据提示拉帕替尼可能对NF2患者脑膜瘤有生长抑制作用,支持对进展性脑膜瘤NF2患者开展拉帕替尼前瞻性研究。

研究设计与样本

  • 回顾性分析在拉帕替尼2期临床试验(NCT00973739)中治疗的NF2及进展性前庭神经鞘瘤患者。
  • 纳入至少1个可体积测量脑膜瘤(>0.5 cm3)且接受至少5个28天疗程的患者,共8例(年龄20-58岁)、17个可评估脑膜瘤。
  • 患者接受拉帕替尼1500 mg每日治疗,脑膜瘤反应采用三维MRI体积测量评估。
  • 进展性脑膜瘤生长和反应分别定义为肿瘤体积较基线变化+20%和-20%;停药定义为任何>5个月未用拉帕替尼的时期。

主要发现

  • 17个脑膜瘤总体积:基线61.35 cc,治疗期间61.17 cc,停药后108.86 cc(+77.44%变化),p=0.0033。
  • 治疗期间和停药期间中位时间分别为15.5个月和16.7个月。
  • 治疗期间年化生长率均值10.67%、中位数1.32%;停药期间均值20.05%、中位数10.42%。
  • 拉帕替尼治疗23个月后最佳体积反应为-26.1%。
  • 治疗期间2个肿瘤体积增加>20%,停药期间8个肿瘤体积增加>20%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Epidermal growth factor receptors EGFR and ErbB2 are overexpressed in schwannomas and meningiomas. Preclinical and clinical data indicate that lapatinib, an EGFR/ErbB2 inhibitor, has antitumor activity against vestibular schwannomas in neurofibromatosis type 2 (NF2) patients. Its antitumor activity against meningiomas, however, is unknown. METHODS: We conducted a retrospective review of patients with NF2 and progressive vestibular schwannomas treated on a phase 2 clinical trial with lapatinib (NCT00973739). We included patients with at least one volumetrically measurable meningioma (> 0.5 cm3) who received at least five 28-day courses of treatment. Patients received lapatinib 1500 mg daily. Meningioma response was assessed using 3-dimensional MRI volumetrics. Progressive meningioma growth and response were defined as + 20 and - 20% change in tumor volume from baseline, respectively. Off-treatment was defined as any period > 5 months without lapatinib. RESULTS: Eight patients (ages: 20-58 years) who met criteria had 17 evaluable meningiomas with a combined volume of 61.35 cc at baseline, 61.17 cc during treatment, and 108.86 cc (+ 77.44% change) off-treatment, p = 0.0033. Median time on-treatment and off-treatment was 15.5 and 16.7 months, respectively. On-treatment mean and median annualized growth rates were 10.67 and 1.32%, respectively. Off-treatment mean and median annualized growth rates were 20.05 and 10.42%, respectively. The best volumetric response was - 26.1% after 23 months on lapatinib. Two tumors increased > 20% volumetrically on-treatment, compared to eight tumors off-treatment. CONCLUSIONS: These data suggest that lapatinib may have growth-inhibitory effects on meningiomas in NF2 patients, and support prospective studies of lapatinib for NF2 patients with progressive meningiomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Osorio DS, Hu J, Mitchell C, et al. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J Neurooncol. 2018. PMID: 29948766. doi:10.1007/s11060-018-2922-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。